Last year, Verve Therapeutics started the first human trial of a CRISPR treatment that could benefit most people—a signal that gene editing may be ready to go mainstream. Explore the meta-data Location Website https://www.technologyreview.com/2023/01/19/1067074/next-for-crispr/ Theme Science & Technology Genetics & bioengineering Population & migrations Postnormal Matters Tags gene editing CRISPR DOI NA
